Abstract
Background
In trecurrent breast cancer, anthracycline-containing chemotherapy is usd to maintain quality of life. However, there are several drawbacks including theraardiotoxicity. We evaluated the efficacy and toxicity of combination chemotherapy-5-fluorouridine (5′-DFUR), medroxyprogestrone acetate (MPA) and mitoxantrone hydrochloride (MIT)
Methods
Sixteanced or recurrent breast cancer were enrolled. Chemotherapy was gle, starting with MIT 10 mg/m2 intravenously on day 1, then oral 5′-DFUR 800 mg anTwo or more cycles were given
Results
Fifteessable for response and toxicity. Thirteen patients had been treated previcycline containing regimen and 2 with CMF. There were 2 partial response patiemplete response patient (6.7%). There were 11 patients showing no change (NC) was a minor responder and 7 with a long period of NC. There was only one wase patient. The overall response rate was 20.0%. Adverse events occurred in 5 patsuppression was the most common with 5 patients becoming leukopenic (33.3was the second most common side effect, affecting 2 patients (13.3%)
Conclusion
Givennd preservation of QOL, the combination of MIT, 5-DFUR and MPA cine therapy for advanced or recurrent breast cancer, especially for anthra-cycline-resistant cases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- CAF:
-
Cyclophosphamide, adriamycin and 5-fluorouracil
- 5-FU:
-
5-fluorouracil
- QOL:
-
Quality of life
- 5′-DFUR:
-
5′-deoxy-5-fluorouridine
- MPA:
-
Medroxyprogesterone acetate
- MIT:
-
Mitoxantrone hydrochloride
- CR:
-
Complete response
- NC:
-
No change
- MR:
-
Minor response
- PD:
-
Progressive disease
- CMF:
-
Cyclophosphamide, methotrexate and 5-fluorouracil
- G-CSF:
-
Granulocyte-stimulating factor
- UFT:
-
Tegafur/uracil
- CA:
-
Cyclophosphamide and adriamycin
- PyNPase:
-
Pyrimidine nucleoside phosphorylase
- HCFU:
-
Carmofur
- TAM:
-
Tamoxifen
References
Harris JR, Morrow M, Bonadonna G: Cancer of the breast. In: De Vita V, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology, 4th ed, J B Lippincott Co, Philadelphia, pp1264–332, 1993.
Early Breast Cancer Trialist’s Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy.Lancet 339:71–85, 1992.
Taguchi T: Chemotherapy for recurrent breast carcinoma.Jpn J Cancer Chemother 12:439–447, 1985.
Cook AF, Holman MJ, Kramer MJ,et al: Fluorinated pyrimidine nucleoside 3, Synthesis and anti-tumor activity of a series of 5′-deoxy-5-fluoropyrimidines.J Med Chem 22:1330–1335, 1979.
Ishizuka H, Miwa M, Takemoto K,et al: Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluorouridine.Gann 71:112–123, 1980 (in Japanese with English abstract).
Niitani H, Kimura K, Saito T,et al: Phase II study of 5′- deoxy-5-fluorouridine (5′-DFUR) on patients with malignant cancer.Jpn J Cancer Chemother 12:2044–2051, 1985.
Koyama H, Nishizawa S, Noguchi S,et al: A combina- tion therapy with 5′-DFUR and MPA as a second line treatment for advanced/recurrent breast cancer.J Jpn Soc Cancer Ther 25:655–661, 1990.
Smith IE: Mitoxantrone (Novantrone): A review of experimental and early clinical studies.Cancer Treat Rev 10:103–115, 1983.
Japanese Breast Cancer Society: General Rules for Clinical and Pathological Recording of Breast Cancer. 12th ed, Kanehara Shuppan, Tokyo, pp58–68, 1996.
Fume H, Hara Y, Imai Y,et al: II. Criteria for the evaluation of effect reinforcement of solid cancer chemotherapy.J Jpn Soc Cancer Ther 28:119–130, 1993.
Yayoi E, Takatsuka Y, Maeura Y,et al: Comparison of response to 5′-deoxy-5-fluoropyrimidine therapy alone in combination with tamoxifen or medroxypro- gesterone acetate in advanced and recurrent breast cancer.Int J Oncology 5:27–32, 1994.
Uchino J, Hata O, Sasaki F,et al: Comparative study of treatment using only 5′-DFUR vs combinated treatment of 5′-DFUR and MPA for advanced or recurrent breast cancer.KARKINOS 4:1295–1300, 1991.
Toi M, Taguchi T, Tominaga T,et al: The effect of combination treatment consisted of 5′-deoxy-5-fluo- ropyrimidine and medroxyprogesterone acetate for recurrent breast cancer patients.Jpn J Cancer Chemother 22:799–844, 1995.
Kusama M, Kimura K, Koyanagi Y,et al: Effects of 5′- DFUR plus Medroxyprogesterone (MPA) in breast cancer patients with bone metastasis.J Jpn Soc Cancer Ther 28:1334, 1993
Cornbleet MA, Stuart-Harris RC, Smith IE,et al: Mitoxantrone for the treatment of advanced breast cancer: Single-agent therapy in previously untreated patients.Eur J Cancer Clin Oncol 20:1141–1146, 1984.
Marsoni S, Wittes R: Clinical development of anticancer agents: A National Cancer Institute Perspective.Cancer Treat Rep 68:77–85, 1984.
lino Y, Yokoe T, Sugamata N,et al: A combination chemoendocrine therapy of mitoxantrone, doxifluri- dine, and medroxyprogesterone acetate for anthracy- cline-resistant advanced breast cancer.Cancer Chemother Pharmacol 41:243–247, 1998.
Howell A, Mackintosh J, Jones M,et al: The defini- tion of the ‘No Change’ category in patinents treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast.Eur J Cancer Clin Oncol 24:1567–1572, 1988.
Author information
Authors and Affiliations
About this article
Cite this article
Sato, K., Hiraide, H., Tamakuma, S. et al. 5′-deoxy-5-fluorouridine, medroxyprogestrone acetate and mitoxantrone hydrochloride for advanced or recurrent Breast Cancer. Breast Cancer 8, 58–62 (2001). https://doi.org/10.1007/BF02967479
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02967479